Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Paxalisib by Kazia Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Paxalisib by Kazia Therapeutics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval
Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase I for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)....
Paxalisib by Kazia Therapeutics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval
Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase I for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)....